Body composition and metastatic prostate cancer survivorship

Cancer Treat Res Commun. 2021:27:100322. doi: 10.1016/j.ctarc.2021.100322. Epub 2021 Jan 24.

Abstract

There is a growing body of evidence related to the importance of body composition in cancer survivorship. Current evidence exclusive to the metastatic prostate cancer setting is limited, yet sheds light on the importance of body composition to reduce risk of mortality and disease progression in this patient population. In our commentary we present the current state of evidence related to body composition and metastatic prostate cancer survival among metastatic castration-resistant and castration-sensitive prostate cancer patients among varying treatment modalities. Additionally, we discuss the proposed biological mechanisms that may underpin how favorable changes in body composition may be helpful for survivorship, and review promising lifestyle strategies that can be implemented as part of survivorship care to improve body composition in this patient population.

Keywords: Androgen deprivation; Body composition; Docetaxel; Metastatic prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Body Composition*
  • Cancer Survivors / statistics & numerical data
  • Disease Progression
  • Docetaxel / therapeutic use
  • Humans
  • Male
  • Progression-Free Survival
  • Prostate / pathology
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / mortality*
  • Prostatic Neoplasms / pathology
  • Survivorship*

Substances

  • Androgen Antagonists
  • Docetaxel